4-hexyl-5-(1-methoxycarbonyl-4-piperidyl)-3-isoxazolol | 439944-62-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-hexyl-5-(1-methoxycarbonyl-4-piperidyl)-3-isoxazolol
• 英文别名: Methyl 4-(4-hexyl-3-hydroxyisoxazol-5-yl)piperidine-1-carboxylate；methyl 4-(4-hexyl-3-oxo-1,2-oxazol-5-yl)piperidine-1-carboxylate
• CAS: 439944-62-4
• 化学式: C₁₆H₂₆N₂O₄
• 分子量: 310.393
• InChiKey: IZCITFXNVJZPRA-UHFFFAOYSA-N

物化性质

• 熔点：
  95-97 °C
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-hexyl-5-(1-methoxycarbonyl-4-piperidyl)-3-isoxazolol 在 氢溴酸 、 溶剂黄146 作用下， 反应 16.0h， 以43%的产率得到4-Hexyl-5-piperidin-4-yl-1,2-oxazol-3-one;hydrobromide
  参考文献：
  名称：

  Novel Class of Potent 4-Arylalkyl Substituted 3-Isoxazolol GABA_A Antagonists:  Synthesis, Pharmacology, and Molecular Modeling

  摘要：

  A number of analogues of the low-efficacy partial GABA(A) agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABA(A) receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABA(B) receptor sites or GABA uptake, they did show affinity for the GABA(A) receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (K-i = 9.1 muM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (K-i = 0.074 muM and K-i = 0.049 muM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABA(A) agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 muM and IC50 = 0.02 muM) comparable with or markedly higher than that of the standard GABA(A) antagonist 4 (IC50 = 0.24 muM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 mumol/kg) and 7s (ED50 = 0.21 mumol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABA(A) receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o,m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.

  DOI：

  10.1021/jm020027o
• 作为产物：
  描述：

  1-(甲氧基羰基)哌啶-4-羧酸 在 sodium hydroxide 、 氯化亚砜 、 盐酸羟胺 、 sodium ethanolate 、 三乙胺 、 magnesium chloride 作用下， 以 甲醇 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.33h， 生成 4-hexyl-5-(1-methoxycarbonyl-4-piperidyl)-3-isoxazolol
  参考文献：
  名称：

  Novel Class of Potent 4-Arylalkyl Substituted 3-Isoxazolol GABA_A Antagonists:  Synthesis, Pharmacology, and Molecular Modeling

  摘要：

  A number of analogues of the low-efficacy partial GABA(A) agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABA(A) receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABA(B) receptor sites or GABA uptake, they did show affinity for the GABA(A) receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (K-i = 9.1 muM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (K-i = 0.074 muM and K-i = 0.049 muM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABA(A) agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 muM and IC50 = 0.02 muM) comparable with or markedly higher than that of the standard GABA(A) antagonist 4 (IC50 = 0.24 muM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 mumol/kg) and 7s (ED50 = 0.21 mumol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABA(A) receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o,m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.

  DOI：

  10.1021/jm020027o